Cargando…
Albumin administration in the acutely ill: what is new and where next?
Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawback...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223404/ https://www.ncbi.nlm.nih.gov/pubmed/25042164 http://dx.doi.org/10.1186/cc13991 |
_version_ | 1782343191497801728 |
---|---|
author | Vincent, Jean-Louis Russell, James A Jacob, Matthias Martin, Greg Guidet, Bertrand Wernerman, Jan Roca, Ricard Ferrer McCluskey, Stuart A Gattinoni, Luciano |
author_facet | Vincent, Jean-Louis Russell, James A Jacob, Matthias Martin, Greg Guidet, Bertrand Wernerman, Jan Roca, Ricard Ferrer McCluskey, Stuart A Gattinoni, Luciano |
author_sort | Vincent, Jean-Louis |
collection | PubMed |
description | Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which groups of patients are most likely to benefit from their use. However, many questions remain related to where exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill patients. |
format | Online Article Text |
id | pubmed-4223404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42234042015-07-16 Albumin administration in the acutely ill: what is new and where next? Vincent, Jean-Louis Russell, James A Jacob, Matthias Martin, Greg Guidet, Bertrand Wernerman, Jan Roca, Ricard Ferrer McCluskey, Stuart A Gattinoni, Luciano Crit Care Review Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which groups of patients are most likely to benefit from their use. However, many questions remain related to where exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill patients. BioMed Central 2014 2014-07-16 /pmc/articles/PMC4223404/ /pubmed/25042164 http://dx.doi.org/10.1186/cc13991 Text en Copyright © 2014 Vincent et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Vincent, Jean-Louis Russell, James A Jacob, Matthias Martin, Greg Guidet, Bertrand Wernerman, Jan Roca, Ricard Ferrer McCluskey, Stuart A Gattinoni, Luciano Albumin administration in the acutely ill: what is new and where next? |
title | Albumin administration in the acutely ill: what is new and where next? |
title_full | Albumin administration in the acutely ill: what is new and where next? |
title_fullStr | Albumin administration in the acutely ill: what is new and where next? |
title_full_unstemmed | Albumin administration in the acutely ill: what is new and where next? |
title_short | Albumin administration in the acutely ill: what is new and where next? |
title_sort | albumin administration in the acutely ill: what is new and where next? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223404/ https://www.ncbi.nlm.nih.gov/pubmed/25042164 http://dx.doi.org/10.1186/cc13991 |
work_keys_str_mv | AT vincentjeanlouis albuminadministrationintheacutelyillwhatisnewandwherenext AT russelljamesa albuminadministrationintheacutelyillwhatisnewandwherenext AT jacobmatthias albuminadministrationintheacutelyillwhatisnewandwherenext AT martingreg albuminadministrationintheacutelyillwhatisnewandwherenext AT guidetbertrand albuminadministrationintheacutelyillwhatisnewandwherenext AT wernermanjan albuminadministrationintheacutelyillwhatisnewandwherenext AT rocaricardferrer albuminadministrationintheacutelyillwhatisnewandwherenext AT mccluskeystuarta albuminadministrationintheacutelyillwhatisnewandwherenext AT gattinoniluciano albuminadministrationintheacutelyillwhatisnewandwherenext |